Impacto 2.0: Mobile Smoking Cessation Across Texas
Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas
This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.
調査の概要
詳細な説明
This project proposes a preliminary efficacy randomized clinical trial (RCT) testing Impacto 2.0, a culturally adapted, bilingual (Spanish and English), smartphone-based smoking cessation intervention developed and pilot tested among Hispanic adults who smoke.
Impacto was originally developed through a National Institutes of Health (NIH)-funded Phase 1 Small Business Technology Transfer (STTR) project using a community-informed, user-centered design process that integrated input from Hispanic end-users, bilingual developers, and clinical providers serving a predominantly Hispanic population. The app targets anxiety sensitivity (AS), or the fear of anxiety-related bodily sensations, which has been empirically shown to be a robust, modifiable transdiagnostic mechanism that impedes smoking cessation success among Hispanic adults.
In a proof-of-concept open trial of Impacto 1.0, 65.4% of Spanish-speaking Hispanic adult participants reported smoking abstinence at 4 weeks post-quit, with significant reductions in anxiety sensitivity and high rates of feasibility, acceptability, and engagement observed across the sample.
The present project aims to extend Impacto 2.0 to Hispanic adults who smoke across Texas, with a statewide targeted recruitment emphasis on rural and medically underserved regions. These regions include communities where geographic, linguistic, and economic barriers may limit access to evidence-based smoking cessation treatment. By leveraging smartphone-based delivery, the study seeks to increase access to culturally adapted smoking cessation support while evaluating the preliminary efficacy of Impacto 2.0 compared to the National Cancer Institute's (NCI) quitSTART app.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Michael J Zvolensky, Ph.D.
- 電話番号:713-743-8056
- メール:mjzvolen@Central.UH.EDU
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77204
- RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
-
コンタクト:
- Angelica G. Duran, B.S
- 電話番号:713-743-8056
- メール:agduran@cougarnet.uh.edu
-
主任研究者:
- Micheal J Zvolensky, Ph.D.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Self-identifies as Hispanic/Latino/a
- Currently resides in Texas
- Age 18 years or older
- Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
- Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
- Motivated to quit smoking
- Able to provide informed consent
- Has daily access to an iPhone or Android smartphone
- Fluent in English or Spanish
Exclusion Criteria:
- Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
- Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
- Current psychotherapy for anxiety or depression
- Concurrent use of medication for anxiety or depression
- Active suicidality (ideation, intent, and/or plan)
- Current psychosis
- Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
- Myocardial infarction within the past 2 weeks
- Uncontrolled high blood pressure
- Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Impacto 2.0
Participants will use the Impacto 2.0 smartphone application for 8 weeks. |
A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity. |
|
アクティブコンパレータ:quitSTART
Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks. |
The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
時間枠:Week 8
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 8
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
時間枠:Week 16
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 16
|
|
Tobacco Withdrawal
時間枠:Baseline, Week 4, Week 8, and Week 16
|
Tobacco withdrawal will be assessed using the revised 15-item Minnesota Nicotine Withdrawal Scale (MNWS), a self-report questionnaire measuring smoking withdrawal symptoms. Items are rated on a 5-point Likert scale ranging from 0 (none) to 4 (severe). A withdrawal severity score is calculated by averaging the core withdrawal symptom items, yielding a score ranging from 0 to 4, with higher scores indicating greater tobacco withdrawal severity. |
Baseline, Week 4, Week 8, and Week 16
|
|
Tobacco Craving
時間枠:Baseline, Week 4, Week 8, and Week 16
|
Tobacco craving will be assessed using the 10-item Questionnaire of Smoking Urges-Brief (QSU-B), which measures cigarette craving in the current moment. Items are rated on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated by summing all 10 items, with possible scores ranging from 10 to 70. Higher scores indicate greater cigarette craving. |
Baseline, Week 4, Week 8, and Week 16
|
|
Anxiety Sensitivity
時間枠:Baseline, Week 4, Week 8, and Week 16
|
Anxiety sensitivity will be assessed using the 5-item Short Scale Anxiety Sensitivity Index (SSASI), which measures fear of anxiety-related bodily sensations. Items are rated on a 5-point Likert scale ranging from 0 (very little) to 4 (very much). The total score is calculated by summing all five items, with possible scores ranging from 0 to 20. Higher scores indicate greater anxiety sensitivity. |
Baseline, Week 4, Week 8, and Week 16
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- STUDY00006201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There is no plan to make individual participant data (IPD) available to other researchers.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。